When ADH1B encodes the beta subunit of [alcohol dehydrogenase | The enzyme family responsible for the first step of alcohol metabolism in the liver, converting ethanol into acetaldehyde], the His48Arg variant (rs1229984, also called ADH1B*2 or Arg47His in older nomenclature) produces an enzyme that operates at a fundamentally different speed. Carriers of the His48 allele — the T allele on the genomic plus strand — have an ADH1B enzyme that metabolizes ethanol to acetaldehyde approximately 70- to 100-fold faster than the common Arg48 form.

The result is predictable: drink alcohol, and your body floods with [acetaldehyde | A reactive aldehyde that causes the characteristic flushing, nausea, and rapid heartbeat. Acetaldehyde is also classified as a Group 1 human carcinogen by the IARC] before your liver can clear it. This is the biological engine behind the "Asian flush" — common in East Asian populations where the His48 allele reaches frequencies of 70-80% or higher.

This is one of the strongest natural deterrents to heavy drinking in the human genome, and one of the most studied protective factors against alcohol use disorder ever identified.

The Mechanism

Alcohol metabolism proceeds in two steps. First, alcohol dehydrogenase (ADH1B) converts ethanol to acetaldehyde. Second, aldehyde dehydrogenase (ALDH2) converts acetaldehyde to harmless acetate. The ADH1B His48 variant supercharges the first step: the enzyme's Vmax for ethanol oxidation is increased roughly 100-fold, producing a surge of acetaldehyde faster than ALDH2 can clear it.

This acetaldehyde surge causes the classic physiological reactions — facial flushing, tachycardia, nausea, headache — within minutes of alcohol consumption. These aversive effects act as a natural deterrent: people who experience them strongly tend to drink less, and often stop drinking altogether. The biological mechanism is essentially the same as the pharmaceutical drug disulfiram (Antabuse), which blocks ALDH2 artificially to create the same acetaldehyde accumulation.

The Arg48 variant (C allele on plus strand), by contrast, produces an enzyme with much lower activity. Arg48/Arg48 carriers metabolize ethanol more slowly, accumulate less acute acetaldehyde, tolerate alcohol better, and face fewer biological barriers to heavy drinking.

The Evidence

Alcohol Use Disorder Protection: The protective effect of the His48 allele is among the most robustly documented findings in psychiatric genetics.

A meta-analysis of 78 studies encompassing 9,638 cases and 9,517 controls¹¹ A meta-analysis of 78 studies encompassing 9,638 cases and 9,517 controls
Li D et al. Strong association of the ADH1B gene with alcohol dependence. Biological Psychiatry, 2011 found that the His48 allele provided greater than 2-fold protection against alcohol dependence in both dominant and allelic models, with the recessive (homozygous His48) model showing OR = 3.05 (P = 9×10⁻²³). The protective effect was strongest in East Asian populations.

In European and African-American populations — where the allele is rare — the protective effect remained genome-wide significant²² In European and African-American populations — where the allele is rare — the protective effect remained genome-wide significant
Bierut LJ et al. ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry. Molecular Psychiatry, 2012: OR = 0.34 (95% CI 0.24-0.48), P = 6.6×10⁻¹⁰.

A meta-analysis specifically of East Asian populations (31 studies, 5,409 cases and 8,182 controls)³³ A meta-analysis specifically of East Asian populations (31 studies, 5,409 cases and 8,182 controls)
Zaso MJ et al. Meta-Analysis on Associations of Alcohol Metabolism Genes With Alcohol Use Disorder in East Asians. Alcohol and Alcoholism, 2019 confirmed the ADH1B*2 allele reduces alcohol use disorder risk with OR = 0.46 in the allelic model and OR = 0.22 in the recessive model, the latter representing a greater than 4-fold protection for His48 homozygotes.

Esophageal Cancer Risk: The same variant has a complex and clinically important relationship with cancer. The core paradox: the His48 allele causes rapid acetaldehyde accumulation, and acetaldehyde is a Group 1 human carcinogen. Carriers of the Arg48 allele (C on plus strand) drink more on average — and sustained alcohol exposure, even at lower acetaldehyde per session, accumulates carcinogenic damage over years.

A meta-analysis of 12 studies (4,220 cases, 8,946 controls)⁴⁴ A meta-analysis of 12 studies (4,220 cases, 8,946 controls)
Zhang G et al. ADH1B Arg47His Polymorphism Is Associated with Esophageal Cancer Risk in High-Incidence Asian Population. PLoS One, 2010 found that the Arg/Arg genotype (CC on plus strand) was associated with OR = 3.86 (95% CI 2.96-5.03) for esophageal squamous cell carcinoma compared to His/His. With heavy alcohol drinking, the Arg/Arg genotype produced an approximately 20-fold increased risk (OR=20.69, 95% CI 5.09–84.13).

A more recent meta-analysis of 23 publications⁵⁵ A more recent meta-analysis of 23 publications
Zhang B et al. Relationship between ESCC risk and alcohol-related ALDH2 and ADH1B polymorphisms. Cancer Medicine, 2023 confirmed ADH1B rs1229984 was associated with 2.50-fold (additive model) increased ESCC risk.

A large Taiwanese cohort (42,665 participants)⁶⁶ A large Taiwanese cohort (42,665 participants)
Chang et al. Impacts of ADH1B rs1229984 and ALDH2 rs671 polymorphisms on risks of alcohol-related disorder and cancer. Cancer Medicine, 2023 reported that the CC genotype conferred OR = 4.10 for esophageal cancer (p<0.001), and that the combination of CC genotype plus ALDH2 deficiency (rs671) increased esophageal cancer risk 381% beyond individual effects alone.

Practical Actions

For His48 carriers (TC or TT genotype): If you experience flushing, nausea, or rapid heartbeat after drinking, your body is signaling real biological harm. These symptoms are not just discomfort — they reflect acetaldehyde accumulation. The deterrent works as a protective mechanism; people who override it and drink through the flush are at elevated risk for upper aerodigestive tract cancers including esophageal squamous cell carcinoma. The single most actionable implication of carrying the His48 allele is: if you flush, the biologically rational choice is to stop, not to push through.

For Arg48 homozygotes (CC genotype): You lack the natural biological deterrent that protects His48 carriers from heavy drinking. You may tolerate alcohol at higher doses without immediate aversive effects, which removes a protective signal that would otherwise limit consumption. If you drink heavily, your cancer risk from sustained alcohol exposure rises substantially — especially if you also carry the ALDH2 rs671 A allele.

The ALDH2 gene (rs671) is the other half of the equation: it encodes the enzyme that clears acetaldehyde. See the Interactions section for combined effects.

Interactions

The two most important variants in alcohol metabolism — ADH1B rs1229984 and ALDH2 rs671 — have documented synergistic effects on both alcohol use disorder and cancer risk.

The ADH1B His48 allele accelerates acetaldehyde production; the ALDH2 Lys487 allele (rs671 A allele) impairs its clearance. Carriers of both a His48 allele and a deficient ALDH2 allele get a double hit: faster production AND slower clearance of acetaldehyde. In East Asian populations, this combination is common and represents the population-level basis for the alcohol flush reaction in its most pronounced form.

For esophageal cancer, the combination of ADH1B Arg48 carriers (CC on plus strand) with impaired ALDH2 showed an OR of 4.81 in the Taiwan cohort — a 381% increased risk — representing additive and synergistic carcinogenic acetaldehyde exposure. Combined with alcohol and smoking⁷⁷ Combined with alcohol and smoking
Cui R et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology, 2009, the risks multiply further.

ADH1B also interacts with rs2066702 (ADH1B*3, Arg370Cys), which provides independent protection against alcoholism primarily in African-ancestry populations, and with ADH1C variants (rs1693482, rs698) that influence the same metabolic pathway.

Your blood pressure during and after stressful moments is not just a product of circumstance — it is partly determined by the genetic brakes your body applies to the sympathetic nervous system. Phosducin (PDC) is one of those brakes, a protein that tempers the cascade of adrenaline signaling in the nerve ganglia that control vascular tone. An intronic variant in the PDC gene (rs12402521) influences how well that brake works — and for people homozygous for the G allele, the brake is weaker.

The Mechanism

Phosducin functions as a G-protein βγ subunit chaperone¹¹ G-protein βγ subunit chaperone
Phosducin sequesters free Gβγ dimers, preventing them from continuing downstream sympathetic signaling. When a postganglionic sympathetic neuron fires, it releases norepinephrine, which activates α- and β-adrenergic receptors on blood vessels and the heart. The termination of this signal depends partly on PDC physically binding to the liberated Gβγ subunit and curtailing its activity. In PDC-deficient mice, postganglionic neurons show prolonged electrical activity, elevated catecholamine turnover, and exaggerated blood pressure spikes in response to post-operative stress — the sympathetic signal keeps running because the brake is missing.

The rs12402521 G allele sits in an intron of PDC and is thought to alter transcript regulation or splicing efficiency, effectively lowering functional phosducin in sympathetic ganglia. The A allele is associated with higher phosducin activity and a more controlled adrenergic response.

The Evidence

The pivotal study by Beetz et al.²² Beetz et al.
Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. J Clin Invest, 2009 combined mouse knockout models with human candidate-gene association data. Pdc-null mice showed elevated catecholamine turnover, prolonged sympathetic neuron firing, and exaggerated blood pressure elevations under surgical stress — without any baseline cardiac or vascular abnormalities, pointing specifically to neural sympathetic dysregulation. In humans, individuals homozygous for the G allele had 12–15 mmHg higher blood pressure than those carrying the A allele, a clinically meaningful difference confirmed across two independent cohorts.

A subsequent review by Broeckel, Stoll & Hein³³ Broeckel, Stoll & Hein
The identification of phosducin as a novel candidate gene for hypertension and its role in sympathetic activation. Curr Opin Nephrol Hypertens, 2011 positioned PDC as a promising therapeutic target for stress-dependent hypertension. The evidence is rated moderate: the mechanism is well-characterised in animal models, and the human association is replicated, but no large-scale GWAS has independently confirmed the variant, and the intronic mechanism is not yet fully elucidated.

Practical Actions

For G/G carriers, the elevated blood pressure effect is specifically stress-linked — triggered by sympathetic overactivation rather than chronic salt or renin-angiotensin dysregulation. Monitoring ambulatory blood pressure during periods of elevated psychological or physiological stress provides more informative data than resting clinic measurements alone. Blunting sympathetic overactivation specifically — rather than generic BP reduction — is the mechanistically targeted strategy.

Interactions

PDC operates upstream in the sympathetic G-protein signaling cascade. Variants in genes encoding adrenergic receptors (ADRB1, ADRB2, ADRA2C) or norepinephrine transporter (SLC6A2) that also amplify sympathetic tone may compound the effect of the G/G PDC genotype. No formally published compound interaction study has been conducted for rs12402521 with these variants, but the shared pathway logic is established.

Your blood carries vitamin B6 mostly as pyridoxal 5'-phosphate (PLP)¹¹ pyridoxal 5'-phosphate (PLP)
The coenzyme form of vitamin B6, required for over 150 enzymatic reactions including amino acid metabolism, neurotransmitter synthesis, and one-carbon metabolism. Before PLP can enter cells from the bloodstream, it must be dephosphorylated to pyridoxal (PL) by membrane-bound tissue-nonspecific alkaline phosphatase (TNSALP)²² tissue-nonspecific alkaline phosphatase (TNSALP)
The enzyme encoded by the ALPL gene, expressed on the surface of liver, bone, kidney, and intestinal cells where it hydrolyzes phosphate groups from PLP to allow cellular uptake — then re-phosphorylated back to PLP inside the cell. ALPL is therefore the gatekeeper for vitamin B6 transport: higher ALPL activity means faster PLP dephosphorylation and quicker cellular uptake, which lowers circulating PLP while keeping intracellular B6 adequate. Lower ALPL activity does the reverse — PLP accumulates in blood while cellular delivery slows. The rs1256335 variant sits in intron 5 of ALPL and influences the gene's regulation. The G allele is associated with higher ALPL expression and enzyme activity — and therefore lower circulating PLP, because the enzyme breaks down PLP more efficiently. Carrying two G copies means measurably lower plasma B6 relative to AA individuals. This does not necessarily mean cellular B6 deficiency — faster dephosphorylation means faster PLP-to-PL conversion and potentially faster cellular uptake — but it does produce lower measured plasma PLP, which is the standard clinical marker of B6 status. Conversely, the A allele is associated with lower ALPL activity, slower PLP dephosphorylation, and higher circulating PLP.

The Mechanism

ALPL encodes tissue-nonspecific alkaline phosphatase³³ tissue-nonspecific alkaline phosphatase
TNSALP, also known as liver/bone/ kidney-type alkaline phosphatase, which is membrane-bound and expressed at highest levels in bone, liver, kidney, and intestine, a phosphomonoesterase that hydrolyzes substrates at alkaline pH. Its physiological substrates include PLP, pyridoxamine phosphate (PMP), and inorganic pyrophosphate⁴⁴ PLP, pyridoxamine phosphate (PMP), and inorganic pyrophosphate
PLP and PMP are phosphorylated vitamers of B6; inorganic pyrophosphate is a mineralization inhibitor whose hydrolysis by ALPL is essential for bone formation. For vitamin B6 metabolism specifically, ALPL cleaves the phosphate from circulating PLP to produce pyridoxal, which crosses cell membranes via facilitated transport, after which intracellular pyridoxal kinase re-phosphorylates it to PLP for enzymatic use. Functional data at this locus comes from a nearby variant, rs1256341, where homozygosity for the minor C allele is linked to reduced ALPL expression in HapMap Northern European ancestry cells⁵⁵ reduced ALPL expression in HapMap Northern European ancestry cells
Carter TC et al. Common Variants at Putative Regulatory Sites of ALPL Influence Circulating PLP. J Nutr, 2015 and correspondingly higher plasma PLP. Importantly, rs1256335 and rs1256341 are nearby but their minor alleles sit on opposite haplotypes — the minor G allele at rs1256335 is associated with lower PLP (higher ALPL activity), while the minor C allele at rs1256341 is associated with higher PLP (lower ALPL activity). These represent partially independent regulatory signals within the ALPL gene region.

The Evidence

The first genome-wide association study of B6 status was published by Tanaka et al. in 2009⁶⁶ Tanaka et al. in 2009
Tanaka T et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet, 2009, identifying the ALPL locus (rs4654748, p = 8.3 × 10⁻¹⁸) as the strongest common genetic determinant of plasma B6 levels across 3,617 participants in four cohorts. A subsequent meta-analysis by Hazra et al. 2009⁷⁷ Hazra et al. 2009
Hazra A et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet, 2009 in 4,763 subjects showed that rs1256335 specifically — the strongest ALPL signal — reaches p = 1.40 × 10⁻¹⁵ with each G allele reducing plasma PLP by approximately 0.14 standard deviation units, while the AA genotype was associated with the highest PLP levels. A candidate gene study in 2,345 Irish adults⁸⁸ candidate gene study in 2,345 Irish adults
Carter TC et al. J Nutr, 2015 found 22 significant ALPL variants, with the PLP-raising effect of the minor allele at the correlated rs1256341 locus corresponding to a median plasma PLP difference of approximately 13 nmol/L between CC (minor) and TT (major) homozygotes (92.2 vs. 78.9 nmol/L). A GWAS of B6 vitamers in cerebrospinal fluid and plasma⁹⁹ GWAS of B6 vitamers in cerebrospinal fluid and plasma
Loohuis LM et al. The Alkaline Phosphatase (ALPL) Locus Is Associated with B6 Vitamer Levels in CSF and Plasma. Genes, 2018 confirmed the ALPL locus association extends to the central nervous system: at this locus, homozygotes for the PLP-raising allele showed a 1.4-fold higher PLP-to-PL ratio in plasma and a 1.6-fold higher ratio in CSF, underscoring that ALPL controls B6 partitioning in both the systemic circulation and the brain. Why does PLP level matter clinically? PLP is an essential cofactor for over 150 enzymatic reactions. Epidemiologically, lower plasma PLP is consistently linked to higher risks: a meta-analysis of 13 prospective studies¹⁰¹⁰ meta-analysis of 13 prospective studies
Larsson SC et al. Vitamin B6 and risk of colorectal cancer: a meta-analysis. JAMA, 2010 found each 100 pmol/mL increase in plasma PLP was associated with a 49% lower risk of colorectal cancer. A large U.S. cohort study found that plasma PLP is inversely associated with CRP, IL-6, and TNF-αR2¹¹¹¹ inversely associated with CRP, IL-6, and TNF-αR2
Sakakeeny L et al. Plasma pyridoxal-5- phosphate is inversely associated with systemic markers of inflammation. J Nutr, 2012, linking B6 status to systemic inflammation independently of diet.

Practical Implications

For AA homozygotes — the majority of people (about 62%) — ALPL activity is lowest at this locus, PLP is turned over slowest, and plasma B6 levels are the highest of the three genotypes. The practical implication is reassuring: this genotype is associated with the highest circulating B6, and dietary B6 requirements may be at the lower end of normal. Standard dietary intake from B6-rich foods is likely sufficient. For GG homozygotes (about 4% of people), ALPL activity is highest, PLP is dephosphorylated most rapidly, and plasma B6 levels are on the lower end. This is not equivalent to deficiency in most cases, but it does mean that dietary B6 intake and B6 bioavailability from food sources matter more for maintaining adequate plasma PLP. Pyridoxal-5-phosphate (P5P) supplements, which bypass the need for ALPL-mediated dephosphorylation on the gut side, may be slightly more efficiently delivered at the cellular level for these individuals compared to pyridoxine supplements that require enzymatic activation.

Interactions

rs1256335 is in partial linkage disequilibrium (r² = 0.16) with rs4654748 in the nearby NBPF3 gene, which was the first GWAS top hit for plasma B6. These two loci represent partially independent signals in the same genomic region. A third variant, rs1256341, also within ALPL, has its minor allele (C) associated with reduced ALPL expression and higher PLP — the opposite direction from rs1256335's minor allele (G). These nearby variants thus capture distinct regulatory effects on ALPL despite their physical proximity. ALPL rs1256335 is also relevant in the context of methylation pathway SNPs¹²¹² methylation pathway SNPs
MTHFR C677T (rs1801133) and SHMT1 C1420T (rs1979277) both require PLP as a cofactor for their enzymatic activity: both MTHFR and SHMT1 are PLP-dependent enzymes. A GG genotype at rs1256335, by reducing circulating PLP, could modestly amplify functional B6 insufficiency when combined with high MTHFR or SHMT1 metabolic demand. However, no published study has formally quantified this combined effect, so this remains a biologically plausible but unconfirmed interaction.

NEDD4L encodes an E3 ubiquitin protein ligase — an enzyme that tags specific proteins for degradation by labelling them with ubiquitin chains. Its most studied target is ENaC, the epithelial sodium channel¹¹ ENaC, the epithelial sodium channel
ENaC controls sodium reabsorption in the kidney collecting duct and is a major determinant of blood volume and blood pressure. NEDD4L ubiquitinates ENaC subunits, marking them for removal from the cell surface. When NEDD4L function falls, ENaC expression rises, more sodium is retained, and blood pressure climbs — the same mechanism that underlies Liddle syndrome, a rare monogenic form of hypertension caused by loss-of- function mutations in ENaC that escape NEDD4L targeting.

Beyond the kidney, NEDD4L is expressed broadly including in the brain, where it ubiquitinates substrates involved in neurodevelopment. It is this neurodevelopmental expression that connects the gene to the rs12606138 signal — a chromosomal 18q locus that has appeared in multiple independent linkage and association studies of developmental dyslexia and general reading ability.

The Mechanism

rs12606138 is an intronic variant in NEDD4L at position 58,326,712 (GRCh38, chr18q21.31). Intronic variants do not change the protein sequence directly, but can affect splicing efficiency, alter exon inclusion, or change regulatory element binding, thereby modulating the amount or isoform composition of NEDD4L protein produced. The precise molecular mechanism by which this variant influences reading ability has not been characterised, and it is possible that rs12606138 is itself a [tag SNP | a marker in linkage disequilibrium with a nearby causal variant rather than the functional change itself] for a functional change elsewhere in the locus.

NEDD4L has 43 exons and produces multiple isoforms expressed in different tissues. Brain-specific isoforms regulate neuronal ubiquitination processes including SMAD2/3 and TGF-β signalling pathways relevant to neuronal migration and cortical development — the same developmental processes disrupted in classical dyslexia neuropathology (ectopias, cortical microgyria).

The Evidence

The association between the chr18q NEDD4L locus and dyslexia was first established through linkage. Six independent studies reported linkage to a broad ~40 Mb region spanning 18p11.2 to 18q12.2 for developmental dyslexia or general reading ability, with NEDD4L identified as one of three candidate genes²² Six independent studies reported linkage to a broad ~40 Mb region spanning 18p11.2 to 18q12.2 for developmental dyslexia or general reading ability, with NEDD4L identified as one of three candidate genes
alongside MC5R and DYM.

The association was then refined to specific variants. In a German dyslexia case-control study of 388 cases and 364 controls, the major A allele of rs12606138 showed risk association with dyslexia (OR 1.35, 95% CI 1.0–1.7, p=0.017)³³ the major A allele of rs12606138 showed risk association with dyslexia (OR 1.35, 95% CI 1.0–1.7, p=0.017)
The variant was in strong LD with rs8094327, suggesting both tag the same causal signal. Notably, the association replicated in a German cohort a signal originally detected in English-speaking populations, indicating the locus acts across linguistic backgrounds — suggesting the biological effect is on neural reading circuitry rather than language-specific learning.

The 2016 Scientific Reports meta-analysis expanded this work with additional German subjects, further supporting the chromosome 18 NEDD4L region contribution to reading ability variance, though the effect at this specific variant remains modest (explained variance < 1%).

The G allele of rs12606138 appears to be the protective minor allele in European and African populations (~18–20%), and is even rarer in East Asian populations (~7%). The major A allele — carried by ~67% of Europeans as homozygotes — is the allele associated with increased dyslexia susceptibility in the German study. Effect sizes are modest: OR 1.35 at the population level, translating to a small absolute risk increase, consistent with a polygenic contribution to a complex neurodevelopmental trait.

Practical Implications

Dyslexia is a highly polygenic trait — hundreds of variants each contribute a fraction of a percent of variance. rs12606138 is one signal among many, and having the AA genotype does not predict dyslexia; it slightly shifts a population-level probability. The variant's practical value lies in raising awareness of the genetic architecture of reading difficulty and in research contexts for stratifying cohorts.

For cardiovascular health, NEDD4L's canonical role in ENaC-mediated sodium regulation means variants in this gene can affect salt sensitivity and blood pressure. While rs12606138 specifically has been studied in dyslexia genetics rather than blood pressure GWAS, the gene's expression profile and ubiquitin ligase function remain relevant to renal sodium handling. Monitoring blood pressure and limiting dietary sodium intake is prudent given this gene's established role in the pathway.

Interactions

rs12606138 is in strong linkage disequilibrium with rs8094327, a second NEDD4L intronic variant ~30 kb upstream, and the two variants likely tag the same functional signal. Considering both together does not independently add information beyond one of them.

The chr18q dyslexia locus shows independent signals from chromosome 6p (DCDC2, KIAA0319) and chromosome 3p (ROBO1) — the three most replicated dyslexia linkage regions. These loci appear to contribute independently, with some evidence of additive effects in polygenic score analyses.

IL1RAPL2¹¹ IL1RAPL2
interleukin-1 receptor accessory protein-like 2; gene ID 26280, located at Xq22.3 is a member of the IL-1 receptor superfamily expressed almost exclusively in the central nervous system. Unlike most IL-1 receptor family members that participate in immune signaling, IL1RAPL2 functions as a synaptic adhesion molecule²² synaptic adhesion molecule
a protein that bridges presynaptic and postsynaptic membranes to organize and stabilize connections between neurons — its primary job is building and maintaining connections between neurons, not immune regulation. The gene spans more than a megabase of the X chromosome (Xq22.3) and is closely related to IL1RAPL1, which is an established cause of X-linked cognitive disability and autism when deleted or mutated.

The rs12688128 variant is an intronic substitution (T→A) with no known functional consequence at the protein level. It appears in only one publication: a 2007 Thai study examining genetic susceptibility to thyrotoxic hypokalaemic periodic paralysis³³ thyrotoxic hypokalaemic periodic paralysis
THPP: episodic muscle weakness triggered by excess thyroid hormone, especially in hyperthyroid Asian men; thought to involve potassium shifts into muscle cells.

The Mechanism

IL1RAPL2 protein interacts trans-synaptically with PTPδ⁴⁴ PTPδ
protein tyrosine phosphatase delta, expressed on presynaptic axons; a synaptic organizer that pairs with postsynaptic proteins to specify synapse type and location on the presynaptic axon and with RhoGAP2 in the postsynaptic density. Together, this complex drives the formation of excitatory synapses and dendritic spines — the structural basis of learning and memory. Mouse studies show that Il1rapl2 is expressed in the nervous system from embryonic day 12.5 onward, consistent with a role in circuit assembly during early brain development.

The rs12688128 variant sits within an intron of IL1RAPL2, and no study has demonstrated that it alters splicing, expression, or protein function. Its CADD score of 0.376 and GERP score of −2.76 both indicate low evolutionary constraint and a low predicted functional impact — meaning this specific nucleotide position is not under strong purifying selection. The most plausible interpretation is that rs12688128 is a population-frequency marker in linkage disequilibrium with another variant elsewhere in the Xq22 region that might have functional relevance.

The Evidence

The single study linking rs12688128 to disease is Jongjaroenprasert et al. 2008⁵⁵ Jongjaroenprasert et al. 2008
"Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population." Clin Endocrinol (Oxf) 68:646-51. This group used pooled DNA microarrays (50 THPP cases vs 50 hyperthyroid controls) and identified two SNPs — rs750841 and rs12688128 — that together formed a haplotype with a relative risk of 19 (P<0.0002) for THPP. The paper described both as "GABRA3 variants," but dbSNP places rs12688128 in the IL1RAPL2 intron at chrX:104,747,771, approximately 47 Mb centromeric from GABRA3 at chrX:152,297,246. Whether the original grouping reflects a genomic annotation error, linkage disequilibrium misclassification, or another explanation has not been clarified in subsequent literature.

Critically, this finding was not replicated in a Korean cohort⁶⁶ not replicated in a Korean cohort
Park et al. 2016, Endocrinol Metab (Seoul): 48 TPP cases vs 48 non-TPP Graves disease controls; GABRA3 polymorphisms showed OR 1.83, P=0.41 — not significant. The Korean study used a different population and different methodology, so the null result cannot definitively refute the Thai finding, but it means the association has failed its first replication attempt.

A separate reproductive biology connection comes from a 2025 bovine embryo study finding that IL1RAPL2 shows sex-biased differential exon usage in early blastocysts⁷⁷ sex-biased differential exon usage in early blastocysts
Shi et al. 2025, Cell Biosci: male and female bovine embryos activate IL1RAPL2 in sex-specific splice patterns as early as the blastocyst stage. This suggests the IL1RAPL2 locus participates in sex-specific transcriptional programs during early embryo development — relevant context for a variant on the X chromosome that is hemizygous in males and heterozygous in females.

Practical Actions

Because rs12688128 is an intronic variant with no known functional effect on IL1RAPL2 protein, and its only disease association (THPP) is based on a single small unreplicated study, clinical action at this locus is limited. Thyrotoxic hypokalaemic periodic paralysis occurs almost exclusively in the setting of hyperthyroidism (most commonly Graves disease) and resolves when thyroid function is normalized — making the genetic risk modifier of secondary importance compared to thyroid status itself.

For carriers of the A allele who are also hyperthyroid or have Graves disease, awareness that periodic paralysis episodes can occur — and can be severe enough to require emergency potassium supplementation — is the most actionable piece of information from this locus given current evidence.

Interactions

The Thai study identified rs12688128 in combination with rs750841 (an intronic GABRA3 variant). The combined haplotype showed a much larger association than either SNP alone (RR=19), suggesting potential epistatic or haplotype-level effects. GABRA3 encodes the alpha-3 subunit of the GABA-A receptor, which has documented roles in thyroid hormone sensitivity of skeletal muscle ion channels. If the association is genuine, the combination of rs750841 (GABRA3) and rs12688128 (IL1RAPL2) may tag a chromosomal haplotype whose functional variant has not yet been identified. The interaction should not be treated as established without replication.

TYK2 is the most genetically validated drug target in autoimmune disease today. Its pseudokinase (JH2) domain — the regulatory scaffold that controls the adjacent catalytic domain — is a hotspot for naturally occurring protective variants that reduce IL-12, IL-23, and type I interferon signaling without eliminating immune function. The Ile684Ser substitution (rs12720356) is the third and most common of three independent protein-coding protective signals in TYK2, and it provides some of the clearest evidence yet that TYK2 JH2 function is directly tunable by single amino acid changes.

Unlike rs34536443 (p.Pro1104Ala), which operates at the interface that couples the JH2 domain to the kinase (JH1) domain, Ile684Ser sits within the N-lobe of JH2 at a position that positions the αC helix for productive regulation of JH1. Replacing the rigid, hydrophobic isoleucine with a small, polar serine partially disrupts this structural arrangement — reducing but not abolishing TYK2's positive regulatory capacity. The net result is a hypomorphic TYK2 that retains sufficient antiviral and homeostatic signaling while measurably blunting the inflammatory amplification loops that drive autoimmune tissue damage.

The Mechanism

TYK2 mediates cytokine signaling downstream of the IL-12 receptor (activating JAK2-STAT4), IL-23 receptor (activating STAT3/STAT4), and type I interferon receptors IFNAR1/2 (activating JAK1-STAT1-STAT2). The JH2 pseudokinase domain acts as an allosteric regulator of the JH1 kinase domain — it both autoinhibits basal activity and potentiates the response to cytokine- driven activation.

Cytrzak-Gorczak et al. (2018)¹¹ Cytrzak-Gorczak et al. (2018) demonstrated directly in human blood that I684S reduces IL-12-stimulated STAT4 phosphorylation²² STAT4 phosphorylation
STAT4 is a transcription factor activated by IL-12 signaling that drives Th1 differentiation and IFN-γ production; reduced pSTAT4 means blunted IL-12-driven T cell polarization toward the Th1 inflammatory phenotype in CD4+ and CD8+ memory T cells. Critically, this reduction was measurable in skin-homing CLA+³³ CLA+
Cutaneous lymphocyte- associated antigen (CLA) marks T cells that home preferentially to skin, making them the relevant effector population in psoriasis T cells — the very immune cell subset responsible for psoriatic inflammation. Type I IFN-α signaling (STAT1/STAT2 pathway) is preserved because the JAK partner can compensate for reduced TYK2 JH2 regulatory capacity in that signaling context.

Fine-mapping of the TYK2 locus⁴⁴ Fine-mapping of the TYK2 locus confirmed that I684S, A928V (rs35018800), and P1104A (rs34536443) sit on three different haplotype backgrounds, establishing their independence. Conditional analysis shows that even after accounting for the stronger P1104A and A928V signals, I684S retains an independent protective effect (OR 0.86, P=4.6×10⁻⁷ for RA), confirming it is a genuine causal variant rather than a tag for the others.

The Evidence

The foundational genetic evidence comes from Diogo et al. (2015)⁵⁵ Diogo et al. (2015), who combined Immunochip dense genotyping, Exomechip genotyping, and targeted exon sequencing across 23,092 RA case/control + 18,409 additional samples. Three independent TYK2 coding signals emerged: P1104A (OR 0.66, P=2.3×10⁻²¹), A928V (OR 0.53, P=1.2×10⁻⁹), and I684S (OR 0.86, P=4.6×10⁻⁷). The same three variants also independently protected against SLE in the same study, supporting their pan-autoimmune relevance.

For psoriasis specifically, Sigurdardottir et al. (2018)⁶⁶ Sigurdardottir et al. (2018) provided functional cellular evidence: the I684S C allele significantly reduced STAT4 phosphorylation following IL-12 stimulation, with the effect measurable in skin-homing memory T cells — a finding that bridges the genetic association to the cellular mechanism responsible for plaque formation.

The meta-analysis by Lee and Bae (2016)⁷⁷ meta-analysis by Lee and Bae (2016), pooling 16,335 patients across 12 studies, confirmed protection for autoimmune rheumatic diseases in Caucasians (OR 0.812, 95% CI 0.661–0.997), though not in Asian populations — consistent with the variant's low frequency in East Asian ancestries. A 2019 study of Mexican patients with SLE⁸⁸ 2019 study of Mexican patients with SLE found strong protection at rs12720356 (OR 0.308 for childhood-onset, OR 0.250 for adult-onset), consistent with the Iberian origin of the C allele in admixed Latin American populations.

Practical Implications

With a European minor allele frequency of approximately 8%, I684S is more common than either A928V (~0.8%) or P1104A (~4%), making it the most population-accessible of the three independent TYK2 protective coding variants. About 15% of Europeans carry at least one C allele at rs12720356. Unlike P1104A — where the pharmacological copy (deucravacitinib) provided indirect evidence for a cancer immune-surveillance trade-off — no analogous cancer-risk signal has been reported for I684S carriers in the published literature.

For heterozygous AC carriers and for the rare CC homozygotes, this variant is relevant in the same clinical contexts as other TYK2 protective alleles: autoimmune workup interpretation, biologic therapy consideration, and family-history counseling for RA, SLE, psoriasis, and T1D. If a TYK2 inhibitor such as deucravacitinib is prescribed, the I684S allele contributes an independent layer of baseline TYK2 attenuation that a prescriber should be aware of.

Interactions

rs12720356 is one of three independent TYK2 protective coding variants confirmed by haplotype analysis to reside on separate haplotype backgrounds (Diogo et al. 2015). The other two are rs34536443 (P1104A, MAF ~4% in Europeans) and rs35018800 (A928V, MAF ~0.8% in Europeans). Individuals carrying C alleles at more than one of these three loci have multiple independent layers of TYK2 JH2 attenuation.

rs2304256 (V362F) — also in TYK2 — operates through a completely different mechanism (exon 8 splicing and FERM domain receptor binding), and fine-mapping has resolved⁹⁹ fine-mapping has resolved that the rs2304256 association signal in SLE and RA GWAS is largely driven by imperfect linkage disequilibrium with the actual causal coding variants, including I684S. The two variants are functionally and genetically independent.

Beyond TYK2, the I684S protective effect acts within the same autoimmune genetic architecture as PTPN22 (rs2476601, T cell receptor threshold) and CTLA4 (rs3087243, costimulation threshold) — variants that modulate T cell activation at different checkpoints and likely confer additive protection when co-inherited with protective TYK2 alleles.

The TRAF3IP2 gene encodes Act1 (also called CIKS — Connection to IKK and Stress-activated protein kinase), the essential scaffolding protein¹¹ the essential scaffolding protein
Act1 is recruited to the cytoplasmic domain of the IL-17 receptor upon IL-17A or IL-17F binding, bridging receptor activation to downstream NF-κB and MAP kinase inflammatory signaling in the IL-17 pathway. When genome-wide association studies scanned the locus looking for the single strongest statistical signal for psoriatic arthritis, rs13190932 — encoding the R74W (Arg74Trp) amino acid substitution in Act1 — emerged as the top hit: P = 8.56 × 10⁻¹⁷, odds ratio 1.83 in the combined sample of over 4,700 individuals of European descent. This is one of the most significant non-HLA association signals in psoriatic arthritis genetics.

The Mechanism

R74W changes arginine to tryptophan at position 74 of Act1, located in the N-terminal region of the protein near its TRAF-binding domain. Critically, functional assays show that R74W does not disrupt TRAF6 binding²² R74W does not disrupt TRAF6 binding
Full-length Act1 constructs carrying R74W showed TRAF6 binding comparable to wild-type in mammalian two-hybrid assays — in sharp contrast to the D10N variant (rs33980500) which loses ~90% of TRAF6-binding capacity. The variant is therefore not itself the mechanistic driver of disease: its disease association derives primarily from strong linkage disequilibrium³³ strong linkage disequilibrium
R²=0.88, D'=0.96 with rs33980500 in European populations, meaning rs13190932-A and rs33980500-T are nearly always inherited together on the same haplotype with the functionally causal D10N variant (rs33980500).

However, the rs13190932 locus carries independent information beyond simple LD tagging. Haplotype analysis in 2,077 PsA cases and 2,648 controls revealed that a four-SNP haplotype including both rs13190932 and rs33980500 carries an odds ratio of 2.7 for psoriatic arthritis⁴⁴ a four-SNP haplotype including both rs13190932 and rs33980500 carries an odds ratio of 2.7 for psoriatic arthritis
This four-SNP haplotype is substantially more predictive than either variant alone, suggesting that regulatory or structural effects from multiple alleles act in concert at this locus. Importantly, rs33980500 (D10N) appears on an additional rarer haplotype background that does not carry rs13190932-A; rs13190932 tracks a subset of the haplotype space that may be particularly enriched for joint (arthritis) versus skin-only (psoriasis vulgaris) disease manifestation.

The Evidence

The initial discovery cohort was 609 German individuals with psoriatic arthritis and 990 controls⁵⁵ 609 German individuals with psoriatic arthritis and 990 controls
Discovery was followed by replication across 6 additional European cohorts totaling 5,488 individuals; combined analysis: OR=1.83 (95% CI 1.59–2.12), P=8.56×10⁻¹⁷. The PsA association (P=8.56×10⁻¹⁷) is approximately 10,000-fold more significant than the psoriasis vulgaris association at the same SNP (P=1.95×10⁻³), suggesting that while rs13190932 tags a shared TRAF3IP2 risk haplotype, the haplotype it tracks is particularly enriched for patients who develop joint involvement.

The variant is essentially monomorphic in East Asian populations⁶⁶ essentially monomorphic in East Asian populations
Both rs13190932 and rs33980500 showed no polymorphism in Han Chinese cohorts studied for Behçet's disease and Vogt-Koyanagi-Harada syndrome — consistent with near-zero allele frequency in East Asian populations in gnomAD. This mirrors the marked ancestral stratification seen in psoriatic arthritis genetics more broadly, where European-derived loci often show minimal variation in East Asian populations that have a distinct psoriasis genetic architecture.

Beyond psoriatic arthritis and psoriasis, rs13190932 has been evaluated across the spectrum of IL-17-pathway autoimmune disease. In systemic lupus erythematosus, all three TRAF3IP2 coding variants (rs33980500, rs13190932, rs13193677) associate with pericarditis development⁷⁷ associate with pericarditis development
Italian cohort of SLE patients: all three TRAF3IP2 SNPs associated with pericarditis; rs13190932-A specifically associated with malar rash (OR=2.14, P=0.041), suggesting the haplotype marked by rs13190932 influences IL-17-mediated vascular and mucocutaneous inflammation across autoimmune contexts.

Practical Implications

Because R74W is not itself the mechanistic driver of disease — its signal derives from LD with D10N — the clinical and practical implications of rs13190932 are best understood as a read-out of the broader TRAF3IP2 risk haplotype. Individuals carrying the A risk allele have substantially elevated psoriatic arthritis risk and warrant the same monitoring and management considerations as D10N (rs33980500) carriers.

The primary practical value of genotyping rs13190932 is as an LD sentinel⁸⁸ LD sentinel
Sentinel variants mark disease association peaks in GWAS; they provide risk stratification even when they are not themselves the causal variants, because they reliably travel with the causal variant in the population for the full TRAF3IP2 risk haplotype. If a genome report includes rs13190932 but not rs33980500, the A allele at rs13190932 provides robust risk stratification for psoriatic arthritis at this locus.

For biologic therapy decisions, the same considerations as D10N apply: the TRAF3IP2 risk haplotype marked by rs13190932 signals impaired canonical IL-17→TRAF6→NF-κB signaling. Anti-IL-17 agents (secukinumab, ixekizumab, brodalumab) and anti-IL-23 agents (guselkumab, risankizumab) each target distinct points in the upstream pathway and may merit consideration relative to anti-TNF agents depending on joint versus skin disease predominance.

Interactions

rs13190932 and rs33980500 (D10N) are in very high LD (R²=0.88) and almost always travel together on the same haplotype. The four-SNP haplotype that includes both variants, plus rs13210247 and rs13196377, carries an OR of 2.7 for psoriatic arthritis — substantially higher than either coding variant alone, indicating additive haplotype effects likely from regulatory variants in non-coding intervals.

The rs13190932 risk haplotype operates within the broader IL-17/Th17 axis. HLA-C rs12191877⁹⁹ HLA-C rs12191877
tags HLA-Cw*0602, the dominant psoriasis susceptibility allele; confers ~30-fold increased risk for type I psoriasis via impaired self-tolerance at the T-cell level creates a dual-hit with the TRAF3IP2 locus: impaired immunological tolerance upstream (HLA) combined with altered IL-17 adaptor signaling downstream (TRAF3IP2). Carriers of both loci likely face synergistic psoriasis and psoriatic arthritis risk that warrants early specialist engagement.

Your immune system's type I interferon alarm — orchestrated by Interferon Regulatory Factor 5 (IRF5) — is one of the most powerful switches in human innate immunity. When this switch runs too loud and too long, the result is chronic inflammatory damage seen in systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis. rs13245639 sits in the 5' upstream regulatory region of IRF5 at chromosome 7, position 128,927,756 (GRCh38), and represents one of the most functionally characterized cis-regulatory variants at this locus. In near-perfect linkage disequilibrium (r²=0.97) with the established protective tag SNP rs729302, rs13245639 is not merely a proxy — its T allele directly shows allele-specific transcription factor binding¹¹ transcription factor binding
Detected by electrophoretic mobility shift assay (EMSA): a technique that reveals whether nuclear proteins bind differently to two alleles of a DNA sequence and lower IRF5 expression in reporter gene assays, making it a functional candidate for the protective effect and arguably a sharper tag on whole-genome sequencing platforms.

The Mechanism

IRF5 operates as a master transcription factor for type I interferon (IFN-α/β) production and for proinflammatory cytokine secretion (IL-12, IL-6, TNF-α) in innate immune cells — monocytes, macrophages, plasmacytoid dendritic cells, and B cells. Overexpression of IRF5 drives the sustained interferon signature characteristic of autoimmune flares. The rs13245639 variant lies within the 5' upstream regulatory architecture of IRF5, approximately 1.15 kilobases from the rs729302 anchor SNP within the same haplotype block.

The functional work by Alonso-Perez et al. 2013²² Alonso-Perez et al. 2013
Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. Arthritis Research & Therapy, 2013 screened 26 candidate cis-regulatory SNPs — selected from 54 genotyped variants across the IRF5 5' region — for functional activity in lymphoblastoid cells. rs13245639 emerged as one of only seven that showed reproducible allele-specific differences in EMSA and one of three (alongside rs729302 itself and an indel at rs11269962) that passed both EMSA and reporter gene assay criteria. In EMSA experiments, the T allele produced a specific band slowdown (band shift) compared with the C allele, indicating that one or more nuclear proteins bind preferentially to the T-allele sequence. The causal transcription factor was not identified — high-throughput bioinformatic tools performed poorly on this region — but the binding difference is reproducible.

In luciferase reporter gene assays, constructs carrying the major C allele of rs13245639 showed significantly higher expression than constructs with the minor T allele (P<0.05, Wilcoxon matched-pairs test). This is the functionally coherent direction: the C allele drives higher IRF5 transcription, the T allele dampens it. Since the T allele travels with the rs729302-C protective haplotype at r²=0.97, the protective biology is mechanistically consistent — the T allele reduces IRF5 output, softening the interferon alarm and lowering autoimmune drive.

The near-perfect LD (r²=0.97) between rs13245639 and rs729302 in European cohorts means the two variants capture essentially the same haplotype signal. On consumer genotyping arrays that include rs729302, this adds little incremental information. However, on whole-genome sequencing platforms — where both sites are called with equal fidelity — rs13245639 may provide superior functional interpretation because its allele-specific expression difference is directly demonstrated, whereas rs729302 remains a functional tag whose causal status is less certain. The rs729302 signal is partly explained by LD with the CGGGG promoter indel; rs13245639 may tag the same underlying causal architecture from a different angle.

The Evidence

The foundational protective signal at the IRF5 5' locus was established in the landmark 14-cohort European SLE study by Ferreiro-Neira et al. 2007³³ Ferreiro-Neira et al. 2007
Ann Rheum Dis 2007 66:1338-41, which genotyped 1,383 SLE cases and 1,614 controls. Two independent signals emerged from the IRF5 locus: a 3' susceptibility signal (tagged by rs10488631, P<10⁻¹⁷) and an opposing 5' protective signal (tagged by rs729302, P<10⁻⁶). The protective signal persisted after conditioning on the susceptibility signal, establishing it as a genuine independent effect. Because rs13245639 is in r²=0.97 LD with rs729302, the T allele directly captures this protective signal.

In rheumatoid arthritis, a meta-analysis of five case-control studies⁴⁴ meta-analysis of five case-control studies
Han et al. 2009, J Rheumatol; 6,582 RA cases and 5,375 controls confirmed that the rs729302-tagged protective allele reduces RA risk (random-effects OR=0.889, 95% CI 0.803–0.977, P=0.015). By virtue of near-perfect LD, the rs13245639-T allele carries the same protective association in RA.

The functional significance of rs13245639 specifically — its EMSA band shift and its lower luciferase expression — was established in vitro by Alonso-Perez et al. 2013. While in vitro data alone constitute moderate rather than strong evidence for an individual SNP's causal role, the convergence with the strong epidemiological signal from rs729302 (which it tags at r²=0.97) and the mechanistically coherent direction (T allele = lower IRF5 = reduced autoimmune drive) supports a moderate-to-strong overall evidence rating for the protective biology of this locus.

Practical Implications

Carrying one or two copies of the T allele at rs13245639 indicates your IRF5 locus carries partial or full protective regulatory architecture in the 5' upstream region. This is the same biology captured by rs729302-C — if you have results from a genotyping array that includes rs729302, your rs13245639 interpretation is almost certainly concordant (r²=0.97 means fewer than 3% of people would show discordant genotypes between the two sites).

The protective effect is additive per T allele, consistent with the additive inheritance pattern seen at rs729302. Heterozygous CT individuals carry one buffered and one unbuffered copy of the IRF5 5' regulatory region; TT homozygotes carry the protective architecture on both chromosomes. Neither genotype guarantees freedom from autoimmune disease — the IRF5 locus is one component of a multigenic autoimmune risk architecture that includes HLA, PTPN22, STAT4, and other contributors. However, the T allele provides real, documented biological buffering of the interferon overactivation that underlies SLE and RA.

The most important context for this variant is the full IRF5 haplotype picture: individuals who carry rs13245639-T (no susceptibility at the 5' locus) alongside rs10488631-TT (no susceptibility at the 3' locus) have the most comprehensively protected IRF5 regulatory configuration currently characterized.

Interactions

rs13245639 is in near-perfect LD with rs729302 (r²=0.97) and travels on the same protective 5' haplotype block. For practical purposes, genotyping rs13245639 and rs729302 provides redundant information; however, on WGS data both are present and rs13245639's functional annotation makes it a useful confirmatory or primary tag.

The 5' protective haplotype tagged by rs13245639-T opposes the 3' susceptibility haplotype tagged by rs10488631 (documented separately). These two haplotype blocks are functionally independent — individuals can carry any combination of the two, and their net IRF5-driven autoimmune susceptibility reflects the additive contributions from both loci.

At the pathway level, IRF5 interacts with STAT4 (rs7574865), the signal transducer downstream of type I interferon. IRF5 drives IFN production; STAT4 amplifies cellular responsiveness to that IFN. rs13245639-T carriers who also carry the STAT4 non-risk genotype benefit from a dual buffer: reduced interferon production and reduced interferon amplification.

BLK (B-lymphoid tyrosine kinase)¹¹ BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells encodes a kinase that plays a critical role in B-cell receptor (BCR) signaling and B-cell development. Acting as an accelerator for BCR-driven activation signals, BLK helps B cells respond to antigen stimulation — but crucially, it also participates in the central tolerance checkpoint²² central tolerance checkpoint
The process by which immature B cells that recognize self-antigens are eliminated or silenced in the bone marrow before they can cause harm that eliminates self-reactive B cells. The rs13277113 SNP sits in the promoter region upstream of the BLK transcription start site: the A risk allele reduces BLK mRNA levels in B-cell lines, and carriers show lower BLK expression³³ carriers show lower BLK expression
Pamuk et al. 2017 measured BLK mRNA in blood samples of 84 SLE patients: expression was 0.52× that of controls in circulating immune cells.

The Mechanism

BLK is a Src-family kinase⁴⁴ Src-family kinase
A family of non-receptor tyrosine kinases including Src, Fyn, Lck, and Lyn. BLK is the B-cell-specific member expressed at high levels in B cells from the pre-B cell stage onward. Within the B-cell receptor signaling complex, BLK phosphorylates downstream substrates that both activate B-cell responses to antigen and help establish negative selection of self-reactive clones. When BLK expression is reduced by the A allele, this tolerance mechanism is partially impaired: B cells that recognize self-antigens escape deletion more readily. The result is a subtle shift toward B-cell hyperactivation and increased autoantibody production⁵⁵ increased autoantibody production
Including anti-dsDNA and anti-Smith antibodies characteristic of SLE, and anti-SSA/SSB antibodies in Sjögren's syndrome, the hallmark of multiple systemic autoimmune diseases.

The variant is located at chromosome 8p23.1 in the FAM167A-BLK locus. Notably, the A allele at rs13277113 is also associated with increased expression of the neighboring gene C8orf13/FAM167A⁶⁶ increased expression of the neighboring gene C8orf13/FAM167A
The risk allele reduces BLK but increases FAM167A expression; the functional consequences of elevated FAM167A remain incompletely characterized, suggesting the regulatory region affects a shared promoter element.

The Evidence

The discovery GWAS⁷⁷ discovery GWAS
Hom G et al. 2008 — 1,311 SLE cases, 1,783 North American controls; replicated in 793 Swedish cases and 857 Swedish controls published in the New England Journal of Medicine identified rs13277113 as a genome-wide significant SLE susceptibility locus (OR=1.39, P=1×10⁻¹⁰). Crucially, the study also showed that the A allele correlated with reduced BLK mRNA levels in B-cell lines, providing direct mechanistic evidence linking a regulatory variant to altered gene expression to disease risk.

Subsequent meta-analyses have firmly established this association. A 2011 meta-analysis⁸⁸ 2011 meta-analysis
Fan et al. — 11,796 SLE cases and 20,271 controls across six studies found an overall A-allele OR of 1.42 with no publication bias and no heterogeneity, supporting a highly consistent effect. The largest 2017 meta-analysis⁹⁹ 2017 meta-analysis
Song and Lee — 17 studies, 22,701 cases, 36,365 controls confirmed OR=1.36 (P<1×10⁻⁸) consistent across Caucasian, Asian, and African populations. A broader autoimmune disease meta-analysis¹⁰¹⁰ broader autoimmune disease meta-analysis
Zeng et al. 2017 — 24 studies, 31,095 cases, 39,077 controls for rs13277113 covering SLE, RA, Sjögren's, and other conditions found rs13277113 A vs G: OR=1.33 (95% CI 1.27–1.39), with the strongest associations in Asian populations.

Beyond SLE, BLK rs13277113 is associated with systemic sclerosis¹¹¹¹ systemic sclerosis
Gourh P et al. 2009: 1,050 SSc cases and 694 controls (North American) + 589 SSc cases and 722 controls (Spanish) (OR=1.32 U.S., OR=1.20 combined), particularly with the limited cutaneous and anti-centromere antibody subsets. A French cohort meta-analysis¹²¹² meta-analysis
Coustet et al. 2011 — 6,078 individuals; strongest effect in diffuse cutaneous SSc (OR=1.27) found additive effects between BLK and BANK1 in driving systemic sclerosis risk.

Clinical observations add important nuance: a Turkish cohort study found that the GA genotype¹³¹³ GA genotype
Pamuk et al. 2017 — 84 SLE patients and 105 controls was present in 48.8% of SLE patients versus 31.4% of controls (p=0.035), and SLE patients with the GA genotype had significantly more disease flares¹⁴¹⁴ disease flares
Assessed by SELENA-SLEDAI flare index: 70% of GA carriers vs 37% of non-carriers experienced flares during follow-up.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — have a modestly elevated lifelong background risk for B-cell-driven autoimmune diseases. The most important practical steps are recognizing the early warning signs and ensuring prompt diagnosis if symptoms emerge. The diseases associated with BLK variants — SLE, Sjögren's syndrome, and systemic sclerosis — are all manageable with modern treatments¹⁵¹⁵ manageable with modern treatments
Including hydroxychloroquine, low-dose corticosteroids, biologics (belimumab, rituximab), and immunomodulatory drugs when caught early, but can cause significant organ damage if untreated.

The genetic risk from rs13277113 is modest in absolute terms — most carriers will not develop autoimmune disease. However, it meaningfully shifts the probability calculation and warrants increased vigilance: unexplained joint pain, persistent fatigue, rashes (especially malar/butterfly rash), Raynaud's phenomenon, persistent dry eyes or mouth, and abnormal inflammatory markers all warrant autoimmune workup in risk-allele carriers.

There are no supplement or dietary interventions proven to counteract BLK-mediated B-cell dysregulation. The actions center on monitoring, early detection, and avoiding immune-modulating triggers where possible.

Interactions

The most clinically relevant epistatic interaction is with BANK1 rs10516487¹⁶¹⁶ BANK1 rs10516487
BANK1 R61H, a missense variant in a B-cell scaffold protein that promotes BCR hyperactivation. In a Mexican Latin-American cohort, individuals carrying risk alleles at both BLK rs13277113 and BANK1 rs10516487 showed an interaction OR of 2.36 (P<0.0001) for primary Sjögren's syndrome — substantially higher than either variant alone. An independent trans-ethnic meta-analysis¹⁷¹⁷ trans-ethnic meta-analysis
Génin et al. 2013 — 1,915 RA cases and 1,915 controls from France, Spain, and Japan found a gene-gene interaction between BLK rs13277113 and BANK1 rs3733197 in rheumatoid arthritis (P=0.037): in individuals with BLK GG genotype, the BANK1 G allele increased RA risk (OR=1.21). Both BLK and BANK1 converge on B-cell receptor signaling; their co-occurrence appears to push B-cell hyperactivation beyond what either variant achieves alone.

BLK risk alleles also show partial overlap¹⁸¹⁸ partial overlap
Both PTPN22 R620W and BLK rs13277113 independently predispose to SLE and RA through distinct B-cell and T-cell tolerance mechanisms with PTPN22 rs2476601 (R620W) in autoimmune disease architecture, though BLK specifically affects B-cell tolerance while PTPN22 affects both B-cell and T-cell receptor signaling thresholds.

Lipoprotein lipase (LPL) is the principal enzyme that clears triglyceride-rich lipoproteins¹¹ triglyceride-rich lipoproteins
Very low-density lipoproteins (VLDL) and chylomicrons — the particles that carry fat from the liver and intestine through the bloodstream from circulation. Most research into LPL genetics has focused on coding variants that change the protein itself. rs13702 works differently: it sits in the 3' untranslated region of the LPL gene, a stretch of mRNA that doesn't code for protein but acts as a regulatory landing pad for microRNAs. The variant's mechanism is one of the clearest examples of non-coding genetic regulation affecting a clinically important phenotype.

The Mechanism

The LPL 3' UTR at rs13702 contains a recognition element for microRNA-410 (miR-410). MicroRNAs are short non-coding RNA molecules that bind to target sequences in mRNA and suppress gene expression — they act as a molecular volume knob, turning down the amount of protein produced. When miR-410 binds its recognition element in the LPL 3' UTR, it reduces LPL mRNA translation, lowering the amount of lipoprotein lipase enzyme made.

The rs13702 T allele (the common reference sequence) preserves this binding site intact. miR-410 binds normally, and LPL expression is held under its natural degree of suppression. The C allele, which disrupts the miR-410 seed-sequence match²² seed-sequence match
The "seed" region of a microRNA is its 6–8 nucleotide core that determines target recognition. A single nucleotide change that disrupts complementarity at the seed is enough to abolish binding entirely, prevents miR-410 from binding. Without this brake, luciferase reporter assays³³ luciferase reporter assays
Laboratory experiments where the LPL 3'UTR is fused to a reporter gene — if the mRNA is suppressed, less light is produced. These assays demonstrated the T allele was suppressed 40% by miR-410 mimics, while the C allele was not suppressed at all showed that the T-allele LPL mRNA is reduced by approximately 40% when miR-410 is present, whereas the C-allele reporter is completely unaffected. The result is that C-allele carriers produce more LPL enzyme, clear triglycerides more efficiently, and generate more HDL cholesterol as a byproduct of lipolysis.

The Evidence

Richardson et al.⁴⁴ Richardson et al.
Richardson K et al. Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. Am J Hum Genet, 2013 performed the definitive characterisation of this variant in a meta-analysis across ten population cohorts. Each copy of the C allele was associated with −0.060 mmol/L lower plasma triglycerides (p = 3.18 × 10⁻⁴²) and +0.041 mmol/L higher HDL cholesterol (p = 1.35 × 10⁻³²) — effects equivalent to roughly a 3–5% reduction in fasting triglycerides per allele copy. The study also showed that the lipid-lowering effect of the C allele was amplified in the presence of higher dietary polyunsaturated fat intake (p = 0.00153 for interaction), adding a dietary dimension to the gain-of-function biology.

The CARDIA study Tang et al.⁵⁵ Tang et al.
Tang W et al. Associations of LPL gene polymorphisms with longitudinal plasma lipid trends in young adults. Circ Cardiovasc Genet, 2010 followed 4,161 individuals for 20 years, finding that the C allele not only conferred lower triglycerides and higher HDL at baseline but also slowed the age-related trajectory of worsening lipids — the protective benefit accumulates over a lifetime.

The PREDIMED randomised controlled trial Corella et al.⁶⁶ Corella et al.
Corella D et al. MicroRNA-410 regulated lipoprotein lipase variant rs13702 is associated with stroke incidence and modulated by diet in the randomized controlled PREDIMED trial. Am J Clin Nutr, 2014 examined stroke incidence and found that T-allele homozygotes had elevated stroke risk compared to C-allele carriers. Crucially, assignment to a Mediterranean diet pattern eliminated this excess risk in T-allele carriers — a direct demonstration that dietary fat quality modifies the consequences of reduced LPL activity through this microRNA mechanism.

Dietary modulation was confirmed by Hammad et al.⁷⁷ Hammad et al.
Hammad et al. Common Variants in Lipid Metabolism-Related Genes Associate with Fat Mass Changes in Response to Dietary MUFA in Adults with Abdominal Obesity. J Nutr, 2019, who found that CC homozygotes on high-MUFA diets achieved significantly greater visceral fat reduction (−216 g vs. +17 g in TT carriers, p = 0.017), suggesting the protective effect of the C allele is potentiated by replacing saturated fat with monounsaturated fat.

The C allele frequency varies considerably by ancestry: approximately 29% in Europeans, 51% in Africans, 20% in East Asians, 24% in South Asians, and 30% in Latinos. Most individuals carry at least one C allele, but around 42% of the global population carries TT — the genotype with standard, unmodified LPL expression.

Practical Implications

This is a protective variant. C-allele carriers benefit from the gain-of-function effect automatically — they clear triglycerides more efficiently and maintain higher HDL. The evidence for TT homozygotes points to a meaningful advantage to optimising LPL activity through diet: replacing saturated fat with monounsaturated and polyunsaturated fats (Mediterranean-style dietary fat quality, not simply fat quantity) appears to partially compensate for the absence of the miR-410 disruption. Omega-3 polyunsaturated fatty acids (EPA and DHA) reduce VLDL secretion and upregulate LPL expression through PPAR-α — a mechanistically relevant intervention for T-allele carriers who lack the genetic braking relief of the C allele.

Interactions

rs13702 and rs264 (LPL intron 6) are both LPL regulatory variants but operate through distinct mechanisms: rs264 modulates intronic regulatory elements or splicing enhancers, while rs13702 specifically disrupts a post-transcriptional miRNA regulatory step. They may reside on independent haplotypes. The gain-of-function coding truncation rs328 (S447X) raises LPL activity through a different route (altered heparin-binding and clearance kinetics) and may combine additively with the rs13702 C allele. APOA5 variants (including rs662799 upstream of the gene) reduce LPL stimulation; TT carriers at rs13702 who also carry APOA5 risk alleles face a compounded deficit in triglyceride clearance capacity.